<DOC>
	<DOC>NCT01031225</DOC>
	<brief_summary>This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression Availability of tissue for analysis ECOG Performance Status 0 or 1 Adequate organ function as defined in the protocol. Must be at least 18 years old and able and willing to sign a written informed consent document Poor venous access requiring an indwelling catheter for study drug administration Women who are pregnant or lactating Ventricular ejection fraction &lt; or = to 55% at baseline Any uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA 9090</keyword>
	<keyword>ganetespib)</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>